SCHEMBL29424972

SCHEMBL29424972

CC(C)(C)OC(=O)N[C@H]1CCC[C@@H]1COc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
CCR1 P32246 1/20 0.46
KDM4E B2RXH2 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
PTGES O14684 4/20 0.43
PTGS2 P35354 1/20 0.43
ATF4 P18848 2/20 0.42
KDM1A O60341 1/20 0.42
SSTR4 P31391 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.41
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
AXL P30530 1/20 0.39
MERTK Q12866 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29424914 0.88 LMNA (0.42) ALDH1A1KDM1ASSTR4KMT2AL3MBTL1
SCHEMBL22090393 0.83 PTGES (0.49) ALDH1A1KDM4ETDP1PTGESPTGS2
SCHEMBL5223410 0.78 CCR1 (0.41) ALDH1A1CCR1KDM4ETDP1KDM1A
SCHEMBL29424933 0.76 AAK1 (0.39) TDP1PTGESKMT2AL3MBTL1
SCHEMBL7377064 0.75 KMT2A (0.47) KDM4EKMT2AL3MBTL1
SCHEMBL8398113 0.75 KMT2A (0.47) KDM4EKMT2AL3MBTL1
SCHEMBL8398115 0.75 KMT2A (0.47) KDM4EKMT2AL3MBTL1
SCHEMBL19177176 0.74 EPHX1 (0.43) KDM1AKMT2AL3MBTL1POLBNFKB1
SCHEMBL26266597 0.74 EPHX1 (0.43) KDM1AKMT2AL3MBTL1POLBNFKB1
SCHEMBL15158941 0.74 BTK (0.48) KDM1AKMT2AL3MBTL1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12331029-B2 Orexin 1 receptor antagonists NXERA PHARMA UK LIMITED (GB) 2025-06-17 US disclosed
US-12240825-B2 Oxexin 1 receptor antagonists NXERA PHARMA UK LIMITED (GB) 2025-03-04 US disclosed
US-20220098165-A1 OXEXIN 1 RECEPTOR ANTAGONISTS NXERA PHARMA UK LIMITED (GB) 2022-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098165-A1 OXEXIN 1 RECEPTOR ANTAGONISTS HCRTR1, HCRTR2, OXTR ALDH1A1 1901/4885CCR1 987/4885KDM4E 1658/4885
US-12240825-B2 Oxexin 1 receptor antagonists HCRTR1, HCRTR2, OXTR ALDH1A1 1901/4885CCR1 987/4885KDM4E 1658/4885
US-12331029-B2 Orexin 1 receptor antagonists HCRTR1, HCRTR2, NPY1R ALDH1A1 1992/4885CCR1 721/4885KDM4E 2165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.